| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Atara Biotherapeutics, Inc. (ATRA) has 3 insiders with recent SEC Form 4 filings, including 3 buys and 2 sells. ATRA is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 1.32M | $13.68M | - | |
| CEO | 143.1K | $1.48M | - | |
| Other | 52.0K | $537.7K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Apr 23, 2015 | Ciechanover Isaac E. | Chief Executive Officer | Sell | 5,200 | $61.36 | $319,046.00 | -0.7% | |
| Mar 10, 2015 | Marcus Joel S68 | Director | Buy | 4,000 | $29.57 | $118,285.00 | +160.0% | |
| Feb 18, 2015 | Gallagher Carol Giltner | Director | Buy | 11,000 | $18.00 | $198,000.00 | +21.3% |